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of Experimental Medicine and Immunotherapeutics, Department of Medicine, University of Cambridge, Cambridge, UK; and
10QIMR Berghofer Institute of Medical Research, Brisbane, AustraliaIntroduction: Classification of acute kidney injury (AKI) requires a premorbid baseline creatinine, often
unavailable in studies in acute infection.
Methods: We evaluated commonly used surrogate and imputed baseline creatinine values against a
“reference” creatinine measured during follow-up in an adult clinical trial cohort. Known AKI incidence
(Kidney Disease: Improving Global Outcomes [KDIGO] criteria) was compared with AKI incidence classi-
fied by (1) back-calculation using the Modification of Diet in Renal Disease (MDRD) equation with and
without a Chinese ethnicity correction coefficient; (2) back-calculation using the Chronic Kidney Disease–
Epidemiology Collaboration (CKD-EPI) equation; (3) assigning glomerular filtration rate (GFR) from age
and sex-standardized reference tables; and (4) lowest measured creatinine during admission. Back-
calculated distributions were performed using GFRs of 75 and 100 ml/min.
Results: All equations using an assumed GFR of 75 ml/min underestimated AKI incidence by more than
50%. Back-calculation with CKD-EPI and GFR of 100 ml/min most accurately predicted AKI but mis-
classified all AKI stages and had low levels of agreement with true AKI diagnoses. Back-calculation using
MDRD and assumed GFR of 100 ml/min, age and sex-reference GFR values adjusted for good health, and
lowest creatinine during admission performed similarly, best predicting AKI incidence (area under the
receiver operating characteristic curves [AUC ROCs] of 0.85, 0.87, and 0.85, respectively). MDRD back-
calculation using a cohort mean GFR showed low total error (22%) and an AUC ROC of 0.85.
Conclusion: Current methods for estimating baseline creatinine are large sources of potential error in
acute infection studies. Preferred alternatives include MDRD equation back-calculation with a population
mean GFR, age- and sex-specific GFR values corrected for “good health,” or lowest measured creatinine.
Studies using surrogate baseline creatinine values should report specific methodology.
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he estimation of AKI incidence in clinical trials
presents a number of challenges. Composite end-
points of major adverse outcomes such as mortality,
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International Reports (2021) 6, 645–656need for renal replacement therapy (RRT) or progres-
sion to chronic kidney disease (CKD) are not always
logistically feasible or appropriate. The significance of
under- or overestimation of AKI has significant impli-
cations as the long-term sequelae of even small rises in
creatinine are becoming clearer.1,2 Consensus defini-
tions of AKI3–5 allow classification of small short-term
changes in creatinine; however, all require a premorbid
baseline creatinine as a reference point. The steady
state of creatinine is influenced by many factors during
AKI, including catabolic states,6 total fluid645
Table 1. Abbreviations, definitions, and methods for imputed and surrogate creatinine values
Abbreviation Derivation Equation used eGFR (ml/min per 1.73 m2) Notes
CrRef Reference - - Reference creatinine (nadir follow-up creatinine)
eCr75M Estimate MDRD 75 -
eCr100M Estimate MDRD 100 -
eCr75c Estimate MDRD 75 Chinese ethnicity
23 correction coefficient applied
eCr100c Estimate MDRD 100 Chinese ethnicity
23 correction coefficient applied
eCr75EPI Estimate CKD-EPI 75 -
eCr100EPI Estimate CKD-EPI 100 -
eCradjusted Estimate MDRD Assigned
a Corrected for “good health”30
eCrCohort Estimate MDRD Calculated
b The cohort mean eGFR, defined as the mean of all individually calculated eGFR values using the follow-up creatinine
eCrRnd Estimate - - Randomly assigned creatinine value using a number generator along a lognorml curve
mCradmit Measured - - Lowest measured creatinine during 72-hour admission (measured 12-hourly)
CKD-EPI, Chronic Kidney Disease–Epidemiology Collaboration equation; eGFR, estimated glomerular filtration rate; MDRD, Modification of Diet in Renal Disease.
aAssigned using reference values for age and sex.29
bA calculated glomerular filtration rate based on patient age and sex using the MDRD equation.
Prefixes:
Prefix e denotes an estimated creatinine value.
Prefix m denotes a measured creatinine value.
Suffixes:
Suffix 75 denotes an assumed eGFR of 75 ml/min per 1.73 m2.
Suffix 100 denotes an assumed eGFR of 100 ml/min per 1.73 m2.
Suffix M denotes a back-calculation using an MDRD-derived formula.
Suffix c denotes a back-calculation using an MDRD-derived formula and a Chinese correction coefficient.
Suffix EPI denotes a back-calculation using an CKD-EPI derived formula.
CLINICAL RESEARCH DJ Cooper et al.: Classifying AKI in Acute Infectiondistribution,7,8 and critical illness,9 and is therefore
heavily influenced by, and variable between, different
clinical presentations.10,11 Due to this non–steady state,
back-calculation is also necessary to allow a comparison
of creatinine, and changes in creatinine, rather than
simply relying on a comparison of measured and esti-
mated baseline GFRs.
Among the methods proposed to determine baseline
creatinine, the mean outpatient creatinine assessed 7
days before admission is thought to be the best.12,13
However, AKI associated with infection frequently af-
fects patients who are unlikely to have documented
prehospitalization creatinine measurements. In addi-
tion, follow-up of patients from clinical trials in these
settings is logistically challenging.
It is often necessary, therefore, to estimate a baseline
creatinine by back-calculation; however, this process is not
standardized or uniform throughout studies.14 The most
frequently used approach,15–17 recommendedby theAcute
Dialysis Quality Initiative working group,3 is to back-
calculate estimated baseline creatinine using the MDRD
equation with an assumed GFR of 75 ml/min per 1.73 m2.
This method has numerous sources of potential error.
The more recently derived CKD-EPI equation uses the
same 4 variables as the MDRD equation; however,
models a different relationship of age, sex, and race with
creatinine.18 Although the CKD-EPI equation improves
the accuracy of GFR estimates, particularly at higher
GFR values,19 back-calculation using an assigned GFR of
75 ml/min per 1.73 m2 demonstrates a poor agreement
between measured and back-calculated baseline creati-
nine values in surgical patients.20 It is not known how
these methods perform in acute infection.646In studies of AKI associated with infection, pop-
ulations are generally younger with a lower body
mass index and expected to have a normal, or near-
normal GFR at baseline, with these accuracies com-
pounded by ethnic and regional differences in
muscle mass and diet.21 Although efforts have been
made to provide correction coefficients to existing
GFR formulae in Japanese22 and Chinese23 pop-
ulations, these modified formulae have not been
evaluated for back-calculation of estimated baseline
creatinine. Furthermore, the large variation in these
coefficients suggests that differences may be due to
methodological issues rather than purely genetic
factors.24
In this study, we use different methods to estimate
baseline creatinine values in a heterogeneous Southeast
Asian population with acute infection, and then
compare the accuracy of these back-calculation
methods with a measured “baseline” creatinine at
follow-up. We further evaluate the accuracy of these
methods in classifying AKI.
METHODS
Population
Patients with Plasmodium knowlesi malaria were
recruited consecutively as part of an adjunctive ther-
apy clinical trial (PACKNOW),25 conducted across 4
hospital sites in Sabah, Malaysian Borneo, between
October 2016 and February 2018. Infection with
P. knowlesi is now the commonest cause of endemic
malaria for people living in Malaysia,26 and commonly
causes AKI.27 Full details of the PACKNOW trial pro-
tocol have been published.25 The 2010 MalaysianKidney International Reports (2021) 6, 645–656
ml
Figure 1. Equations used for back-calculation of creatinine. CKD-EPI, Chronic Kidney Disease–Epidemiology Collaboration; GFR, glomerular
filtration rate; MDRD, Modification of Diet in Renal Disease.
DJ Cooper et al.: Classifying AKI in Acute Infection CLINICAL RESEARCHcensus28 reported that 67.4% of Malaysian citizens in
Sabah were classified as Indigenous, 24.6% were of
Chinese origin, 7.3% of Indian origin, and 0.7% as
“others.”Design
Patients older than 18 years were included in the
analysis if they had a follow-up creatinine measure-
ment at $7 days from study enrollment. Serum creat-
inine was measured at study enrollment (hour 0), then
12-hourly for 72 hours. Malaysian Ministry of Health
guidelines for the management of malaria mandate 2
consecutive negative blood slides for malaria parasites
before discharge. In addition, the PACKNOW trial had
an initial study duration of 72 hours. Participants were
invited to attend study follow-up at 7, 14, and 28 days,
where serum creatinine was measured as part of study
procedures. No participants had a documented pre-
morbid baseline creatinine.Kidney International Reports (2021) 6, 645–656Accuracy of Estimated Surrogate Creatinine
Methods Compared With a Reference Creatinine
Value in a Heterogeneous Southeast Asian Popula-
tion With Acute Infection
As no premorbid baseline creatinine values were
available, each patient’s reference baseline creatinine
(CrRef) for all comparisons was defined as the nadir
creatinine measured at follow-up.
Surrogate baseline creatinine values for each patient
were estimated using the following methods (Method
summaries Table 1; detailed equations in Figure 1):
1. eCr75M: Back-calculation using the modified MDRD
equation assuming all patients had a GFR of 75 ml/
min.
2. eCr100M: Back-calculation using the modified
MDRD equation assuming all patients had a GFR of
100 ml/min.
3. eCr75c: Back-calculation using the modified MDRD
equation with correction coefficient for Chinese647
Figure 2. Participant flow diagram. RRT, renal replacement therapy.
CLINICAL RESEARCH DJ Cooper et al.: Classifying AKI in Acute Infectionethnicity23 assuming all patients had a GFR of 75
ml/min.
4. eCr100c: Back-calculation using the modified MDRD
equation with correction coefficient for Chinese
ethnicity23 assuming all patients had a GFR of 100
ml/min.
5. eCr75EPI: Back-calculation using the CKD-EPI
creatinine equation assuming all patients had a
GFR of 75 ml/min.
6. eCr100EPI: Back-calculation using the CKD-EPI
creatinine equation assuming all patients had a
GFR of 100 ml/min.
7. esCradjusted: Back-calculation using the modified
MDRD equation with GFR assigned using reference
values for age and sex29 and corrected for “good
health.”30
8. eCrCohort: The mean of individual follow-up esti-
mated GFR (eGFR) values calculated using the
MDRD equation and lowest measured follow-up
creatinine to provide a population mean eGFR at
follow-up.
9. eCrRnd: Assigning a creatinine value using a
random number generator along a lognorml curve.
Input parameters were derived by fitting a
lognormal curve to baseline creatinine values (m ¼
0.194, s ¼ 0.182).
10. mCrAdmit: lowest measured creatinine during 72-
hour admission (measured 12-hourly).
The performance of each surrogate baseline creati-
nine value was then evaluated against the reference
creatinine value (CrRef). Patients requiring RRT were
excluded from this analysis due to potential con-
founding from subsequent iatrogenic alterations in
creatinine kinetics during admission and follow-up.
Evaluation of the Accuracy of Estimated Baseline
Creatinine Methods in Predicting AKI
The presence of AKI was determined for each patient
using KDIGO criteria based on the increase from the
reference baseline creatinine (mCrRef) by $0.3 mg/dl or
an increase in serum creatinine to $1.5 times baseline;
presumed to have occurred within the prior 7 days (in
the context of acute P. knowlesi infection).
Each method of estimating a surrogate baseline
creatinine was then used to predict the presence of AKI
for each patient using the same criteria.
The performance of the predicted AKI (including
severity and incidence) for each estimated baseline
creatinine method was then evaluated against the
reference AKI result.
Assays
Serum creatinine was measured at hospital laboratories
by the Jaffe reaction using Abbot reagents on an648Architect c4000 Clinical Chemistry Analyzer (Abbot
Laboratories, Chicago, IL).
Statistical Analysis
Each method was compared against the reference
creatinine (CrRef) using a Bland-Altman analysis, by
plotting the mean of the reference creatinine and the
estimated baseline creatinine ([reference þ estimated]/
2) against the difference (reference – estimated baseline
creatinine) for each patient. An ideal model would give
the difference between the 2 measurements as zero,
thereby having all plotted points along the y ¼ 0 axis.
Bias is defined as the average of the differences, with a
bias farther from zero indicating the estimate is sys-
tematically producing different results (i.e., one
method consistently gives values that are higher or
lower than those from the other by a constant amount).
Precision is defined as 1 SD of the bias, and 95% limits
of agreement as  1.96 SD from the mean. Proportional
bias is calculated as the slope of the regression line of
the Bland-Altman plots and illustrates whether the
difference between estimated baseline creatinine and
reference creatinine is proportional to the reference
creatinine. Wilcoxon signed rank test (matching pairs,
non-normal distribution) was used to compare the
entire estimated baseline distribution with the entire
reference distribution, for each of the different
methods.
Sensitivity and specificity were calculated for each
estimate by comparing true KDIGO classification (using
measured reference creatinine) with the classification
by each estimation method. Kappa statistic (95% con-
fidence interval [CI]) was used to report the level of
agreement between AKI classification and classification
using the reference creatinine. The AUC ROC was used
to compare the accuracy of each method for identifying
AKI compared with the reference creatinine.
All analyses were undertaken with Stata version 12
(StataCorp, College Station, TX) and GraphPad Prism 8
(GraphPad, La Jolla, CA).Kidney International Reports (2021) 6, 645–656
Table 2. Baseline characteristics of study population (n ¼ 247)
Characteristic Male (n [ 208) Female (n [ 39) Cohort (n [ 247)
Age 39.1  14.3 48.2  16.3 40.5  14.9
Weight (kg) 63.2  11.4 56.9  13.4 62.2  11.9
Follow-up CKD or nonresolved AKI,a n (%) 3 (1.4) 0 (0) 3 (1.2)
Severe malaria, n (%) 18 (8.7) 4 (10.3) 22 (8.9)
Number of admission creatinine values available (Median [Range]) 7 (3–7) 7 (4–7) 7 (3–7)
Number of follow-up creatinine values available (Median [Range]) 2 (1–3) 2 (1–3) 2 (1–3)
Follow-up creatinineb (mmol/l)
Mean  SD 0.86  0.18 0.72  0.13 0.84  0.18
Median (IQR) 0.83 (0.77–0.92) 0.73 (0.65–0.78) 0.80 (0.75–0.89)
Min, max 0.49, 2.09 0.54, 1.28 0.49, 2.09
Follow-up eGFRc (ml/min) 104.5  20.1 90.1  18 102.2  20.9
Maximum admission creatinine (mmol/l)
Mean  SD 1.39  1.76 0.92  0.25 1.32  1.63
Median (IQR) 1.03 (0.93–1.2) 0.89 (0.79–1.02) 1.0 (0.91–1.18)
Min, max 0.77, 16.1 0.54, 2.1 0.54, 16.1
Required renal replacement therapy, n (%) 5 (2.4) 0 (0) 5 (2.0)
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; IQR, interquartile range; min, max, minimum, maximum.
aComposite of preexisting CKD and/or nonrecovery of AKI as no previous creatinine results available. Defined as eGFR <60 ml/min and uACR >3.0 mg/mmol at 28 days follow-up. The 3
CKD diagnoses included 40-, 48-, and 65-year-old men. Two had KDIGO stage 3 AKI requiring renal replacement therapy during admission.
bLowest of all creatinine measurements throughout follow-up measurements at 7, 14, or 28 days.
cCalculated using MDRD equation and the lowest of all creatinine measurements throughout follow-up measurements at 7, 14, or 28 days.
Conversion factors for units: serum creatinine in mg/dl to mmol/l, 88.4.
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The PACKNOW study recruited 378 patients, 247 of
whom attended a follow-up appointment and were
included in this analysis (Figure 2). Of these, 92% of
patients returned for day 7 follow-up, 23% for day 14,
and 76% for day 28, with a median number of follow-up
visits of 2 (range 1–3). At follow-up, 62% (n ¼ 153), 8%
(n ¼ 20), and 30% (n ¼ 74) of creatinine values were
identified as being the lowest on days 7, 14, and 28,
respectively. Therewas no statistical difference inmedian
creatinine at day 7 compared with day 28 (0.8 mg/dl
[interquartile range 0.72–0.88] vs. 0.88 mg/dl [inter-
quartile range 0.8–0.1]; P ¼ 0.66). Five patients had a
length of stay>72 hours; each of them requiring RRT and
intensive care unit admission. The patients’ baseline
characteristics are summarized in Table 2. Men and
women are presented separately in Table 2 because (1)
creatinine values are imputed using a different coefficient
depending on sex, and (2) the epidemiology ofP. knowlesi
malaria31,32 results in different median ages of men and
women within this population. Five (2.4%) patients
required acute RRT and were excluded from the evalua-
tion of the estimated baseline creatinine values against
CrRef. All 247 patients were included in the classification
of AKI analysis as, by definition, those requiring acute
RRT were classified as stage 3 AKI by KDIGO criteria.
Accuracy of Estimated Baseline Creatinine Methods
Compared With a Reference Creatinine Value
The Bland-Altman plot distribution of all estimated
baseline creatinine methods differed significantly from
the reference CrRef distribution (Table 3 and Figure 3),Kidney International Reports (2021) 6, 645–656with the exception of eCr100M (Wilcoxon signed rank
P ¼ 0.09). The distribution of the lowest creatinine
during the first 72 hours of admission (mCrAdmit) also
differed significantly to the distribution of the CrRef
(P < 0.001).
All distributions of estimated baseline creatinine
values back-calculated using an assumed GFR of 75
ml/min displayed both large absolute and proportional
bias and poor precision (Figures 3a and c, and 4e). The
eCr100M distribution had the smallest bias (0.002
mg/dl; Figure 3b) and good precision (0.16 mg/dl). The
eCr100EPI distribution (Figure 3f) was the next best
performing in terms of bias (0.05 mg/dl); however,
had poorer precision than all other methods (0.26
mg/dl). The eCr100c distribution (Figure 3d) had a large
negative bias and low precision. The eSCradjusted
(Figure 4g) method had a bias of 0.06 mg/dl and pre-
cision of 0.14 mg/dl. The measured lowest creatinine
during admission (mCrAdmit; Figure 4h) correlated
better with CrRef than the estimated distributions
(r ¼ 0.71), had a relatively small bias of 0.05 mg/dl,
the highest precision of all methods at 0.1 mg/dl,
and a small proportional bias that did not differ from
zero.
Evaluation of the Accuracy of Estimated Baseline
Creatinine Methods in Predicting AKI
Of the 247 patients, 71 (29%) had AKI according to
KDIGO criteria (Table 4). All estimated and measured
methods led to an overestimation of total AKI incidence
when compared with AKI classification using the
reference creatinine (CrRef). The eCr100EPI method had
the lowest total percentage error for correctly649
Table 3. Comparison of the baseline reference serum creatinine distribution to those estimated using different back-calculated or measured methods (mg/dl)
Referenceb
eCr75M (75 ml/min) eCr100M (100 ml/min) eCr75c (75 ml/min)
Estimatedc
eCr100c (100 ml/min) eCr75EPI (75 ml/min) eCr100EPI (100 ml/min) eCradjusted
Measuredd Meane
mCrRef mCrAdmit eCrCohort
Mean  SD (mg/dl) 0.83  0.15 1.06  0.13 0.83  0.10 1.35  0.16 1.05  0.12 1.19  0.15 0.87  0.22 0.77  0.06 0.77  0.14 0.81  0.01
Median (IQR) (mg/dl) 0.80 (0.75–0.88) 1.08 (1.02–1.15) 0.85 (0.80–0.89) 1.34 (1.29–1.46) 1.06 (1.0–1.13) 1.21 (1.11–1.3) 0.96 (0.76–1.03) 0.78 (0.76–0.80) 0.77 (0.69–0.84) 0.83 (0.78–0.87)
Wilcoxona - <0.001 0.09 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 0.3
Min, max (mg/dl) 0.49, 1.77 0.72, 1.24 0.57, 0.97 0.92, 1.57 0.71, 1.22 0.32, 1.38 0.14, 1.09 0.62, 0.87 0.43, 1.63 0.54, 0.94
Correlation, pCrm (r) 0.22** 0.22** 0.22** 0.22** 0.13* 0.13* 0.29** 0.71** 0.21**
Bias (mg/dl) 0.24 0.002 0.52 0.22 0.36 0.05 0.06 0.05 0.02
Precision (mg/dl) 0.17 0.16 0.19 0.17 0.20 0.26 0.14 0.10 0.16
Proportional bias 0.24* 0.62** 0.14 (NS) 0.27* 0.07 (NS) 0.7** 1.3** 0.074 (NS) 0.67**
IQR, interquartile range; NS, not significant.
aP-value of comparison between reference creatinine (mCrRef) and the estimated baseline creatinine method.
bThe lowest measured follow-up creatinine $ 7 days since enrollment.
cEstimated baseline creatinine for each estimation method.
dLowest measured creatinine during 72-hour admission.
eEstimated creatinine using the inverse Modification of Diet in Renal Disease (MDRD) back-calculation method and the population mean glomerular filtration rate at follow-up (calculated using the MDRD equation and lowest measured creatinine at
follow-up at 7, 14, and 28 days).
Wilcoxon signed rank test (paired) for comparison of entire distribution with reference creatinine.
*P < 0.05.
**P < 0.001.
Precision ¼ 1 SD of the mean
95% limits of agreement ¼ 1.98  SD of the mean
r: Spearman’s rho
Bias: total mean difference between estimated and reference creatinine.
Precision: 1 SD of the Bias
Proportional bias: the slope of the regression line of the differences between estimated and reference creatinine against the average of estimated and reference creatinine. A slope of 0 means no proportional bias. P value is the significance of the
deviation of the slope from 0: ***P < 0.0001.
mCrRef : Reference baseline creatinine.
eCr75M: estimated baseline serum creatinine using the MDRD formula with estimated glomerular filtration rate (eGFR) of 75 ml/min.
eCr100M: estimated baseline serum creatinine using the MDRD formula with eGFR of 100 ml/min.
eCr75c: estimated baseline serum creatinine using the MDRD formula and Chinese correction coefficient with eGFR of 75 ml/min.
eCr100c: estimated baseline serum creatinine using the MDRD formula and Chinese correction coefficient with eGFR of 100 ml/min.
eCr75EPI: estimated baseline serum creatinine using the CKI-EPI formula with eGFR of 75 ml/min.
eCr100EPI: estimated baseline serum creatinine using the CKI-EPI formula with eGFR of 100 ml/min.
eCradjusted: Back-calculation using the modified MDRD equation with eGFR assigned using reference values for age and sex29 and corrected for “good health.”30
mCrAdmit: Lowest measured creatinine during 72-hour admission.
eCrCohort: estimated baseline serum creatinine using the MDRD formula with population mean eGFR of 103 ml/min.


















































































Figure 3. Bland-Altman plots of estimated and measured distributions (a–d). Bland-Altman plots of the mean of measured and estimated
creatinine against the difference between measured recovery and estimated creatinine for (a) eCr75M; (b) eCr100M; (c) eCr75c; (d) eCr100c. Dotted
line shows bias (mean difference) and dashed lines show 95% limits of agreement ( 1.96  SD of the mean). eCr75M: estimated baseline serum
creatinine using the MDRD formula with estimated glomerular filtration rate (eGFR) of 75 ml/min. eCr100M: estimated baseline serum creatinine
using the MDRD formula with eGFR of 100 ml/min. eCr75c: estimated baseline serum creatinine using the MDRD formula and Chinese correction
coefficient with eGFR of 75 ml/min. eCr100c: estimated baseline serum creatinine using the MDRD formula and Chinese correction coefficient
with eGFR of 100 ml/min.
DJ Cooper et al.: Classifying AKI in Acute Infection CLINICAL RESEARCHidentifying AKI overall (3%), although misclassified all
KDIGO stages. The difference in classification of AKI
was statistically significant between all estimated and
measured methods and the reference creatinine. The
eCr100M and eCr100EPI methods overestimated AKI by
16% and 3%, respectively; however, sensitivity was
higher for eCr100M (83% compared with 65%), and
eCr100M had a significantly higher area under the ROC
curve (0.85 [95% CI 0.80–0.90] compared with 0.75
[95% CI 0.69–0.81]; P < 0.001). The eCradjusted had a
high sensitivity of 94% and specificity of 79%, with
the highest AUC ROC (0.87 [95% CI 0.83–0.91]).
However, eCradjusted had a large total percentage error
(47%) for correctly identifying AKI, with a predomi-
nant overclassification of stage 1 AKI. mCrAdmit over-
estimated AKI by 22%; however, had a relatively high
sensitivity and specificity of 85% for each, and an AUC
ROC of 0.85 (95% CI 0.80–0.90). There were no statis-
tically significant differences among the AUC ROC for
eCr100, eCradjusted, and mCrAdmit. Although all estimated
methods were highly specific for the detection of stage
3 AKI, false positives were also present for eachKidney International Reports (2021) 6, 645–656method, and mCrAdmit failed to identify 1 of 7 (14%)
patients with stage 3 AKI. The AUC ROC curves are
shown in Supplementary Figures S1 and S2.
The eCr100EPI method had the lowest percentage er-
ror of estimating total AKI incidence; however, also
had the lowest kappa statistic of 0.49 (95% CI 0.45–
0.53). This demonstrates that despite identifying
similar numbers with AKI compared with the reference
group, agreement between individual AKI cases was
low, similar to that seen with eCr75M. The eCr100M,
eCradjusted, and mCrAdmit methods demonstrated similar
interrater agreement, with eCr100M marginally better
than the other 2 methods with a kappa statistic of 0.67
(95% CI 0.64–0.70).
Population Mean GFR
A follow-up eGFR value was calculated using the
MDRD equation and inputting the lowest measured
follow-up creatinine. The mean of these eGFR values
was calculated to provide a cohort mean eGFR at
follow-up. We used the inverse MDRD equation
(Figure 3) to back-calculate a baseline creatinine for651
Figure 4. Bland-Altman plots of estimated and measured distributions (e–h). Bland-Altman plots of the mean of measured and estimated
creatinine against the difference between measured recovery and estimated creatinine for (e) eCr75EPI; (f) eCr100EPI; (g) eCradjusted; (h) mCrAdmit
eCr75EPI: estimated baseline serum creatinine using the CKI-EPI formula with eGFR of 75 ml/min. eCr100EPI: estimated baseline serum creatinine
using the CKI-EPI formula with eGFR of 100 ml/min. eCradjusted: Back-calculation using the modified MDRD equation with eGFR assigned using
reference values for age and sex29 and corrected for “good health.”30. mCrAdmit: Lowest measured creatinine during 72-hour admission.
CLINICAL RESEARCH DJ Cooper et al.: Classifying AKI in Acute Infectioneach patient using the population mean follow-up eGFR
(103 ml/min) and individual age and weight. This
method (eCrCohort) had a sensitivity and specificity for
predicting AKI of 86% (95% CI 76%–93%) and 85%Table 4. Number of patients at each acute kidney injury stage based on
Reference
mCrRef eCr75M (75 ml/min) eCr100M (100 ml/min) eCr100EPI (100
Stage I (% error) 55 20 (64) 67 (22) 34 (-38)
Stage II (% error) 9 5 (44) 5 (44) 17 (89)
Stage III (% error) 7 7 (0) 10 (43) 22 (68)
Total (% error) 71 32 (55) 82 (16) 73 (3)
Sensitivity, % (95% CI) 42 (31–55) 83 (80–86) 65 (53–7
Specificity, % (95% CI) 99 (96–100) 87 (85–89) 85 (79–9
Kappa, statistic (95% CI) 0.49 (0.37–0.61) 0.67 (0.57–0.77) 0.49 (0.37
AUC ROCa (95% CI) 0.71 (0.65–0.76) 0.85 (0.80–0.90) 0.75 (0.69
AUC ROC, area under the receiver operating characteristic curve; CI, confidence interval; esC
aArea under the ROC curve for correctly identifying acute kidney injury (AKI).
Values are n (%) unless otherwise indicated.
mCrRef : Reference baseline creatinine.
eCr75M: estimated baseline serum creatinine using the MDRD formula with estimated glomeru
eCr100M: estimated baseline serum creatinine using the MDRD formula with eGFR of 100 ml/m
eCr100EPI: estimated baseline serum creatinine using the CKI-EPI formula with eGFR of 100 ml/
eCradjusted: Back-calculation using the modified MDRD equation with eGFR assigned using ref
mCrAdmit: Lowest measured creatinine during 72-hour admission.
eCrCohort: estimated baseline serum creatinine using the MDRD formula with population mean
% error defined as ([Estimated n with AKI  Reference n with AKI) / Reference n with AKI) 
652(95% CI 79%–90%), respectively, an AUC ROC of 0.85
(95% CI 0.80–0.90) and a kappa of 0.66. The eCrCohort
distribution (Figure 5i) did not differ significantly from
the CrRef distribution (Wilcoxon signed rank test P ¼Kidney Disease: Improving Global Outcomes staging
Estimated Measured
ml/min) eCradjusted eCrCohort esCrRnd mCrAdmit
88 (60) 72 (31) 60 (9) 72 (31)
6 (33) 6 (33) 15 (67) 9 (0)
10 (43) 10 (43) 9 (29) 6 (14)
104 (47) 88 (24) 84 (18) 87 (22)
6) 94 (86–98) 86 (76–93) 75 (71–78) 85 (74–92)
0) 79 (72–85) 85 (79–90) 84 (82–85) 85 (79–90)
–0.61) 0.64 (0.55–0.74) 0.66 (0.56–0.76) 0.55 (0.52–0.59) 0.66 (0.56–0.76)
–0.81) 0.87 (0.83–0.91) 0.85 (0.80–0.90) 0.79 (0.77–0.81) 0.85 (0.80–0.90)
rRnd, randomly assigned creatinine value along a lognormal curve.
lar filtration rate (eGFR) of 75 ml/min.
in.
min.
erence values for age and sex29 and corrected for “good health.”30
eGFR of 103 ml/min.
100.
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Figure 5. Bland-Altman plots of estimated and measured distributions (i and j). Bland-Altman plots of the mean of measured and estimated
creatinine against the difference between measured recovery and estimated creatinine for (i) eCrCohort; (j) eCrRnd. eCrCohort: estimated baseline
serum creatinine using the MDRD formula with population mean eGFR of 103 ml/min. eCrRnd: Assigning a creatinine value using a random
number generator along a lognorml curve.
Figure 6. Receiver operating characteristic curve analysis of the
performance of eCrRnd and eCr100M at identifying acute kidney injury
compared with CrRef.
eCrRnd: Assigning a creatinine value using a random number
generator along a lognorml curve.
eCr100M: estimated baseline serum creatinine using the MDRD formula
with eGFR of 100 ml/min. CrRef : Reference baseline creatinine.
DJ Cooper et al.: Classifying AKI in Acute Infection CLINICAL RESEARCH0.3), and had a small bias (0.02 mg/dl) with a precision
of 0.16 mg/dl.
Randomly Assigned Creatinine Values Along a
lognormal Curve
We randomly assigned a creatinine value along a
lognormal curve for each participant using the Stata
rnormal command, with input parameters generated by
fitting a lognormal curve to the reference creatinine
(m ¼ 0.194, s ¼ 0.182). This method (eCrRnd) had a
sensitivity and specificity for predicting AKI of 75%
(95% CI 71%–78% ) and 84% (95% CI 82%–85%),
respectively, an AUC ROC of 0.79 (95% CI 0.77–0.81),
and a kappa of 0.55.
We assessed the performance of eCr100M (back-
calculation using the MDRD equation and an assumed
eGFR of 100 ml/min per 1.73 m2) against that of
randomly assigning a creatinine value against a
lognormal curve by a comparison of both of these ROC
curves to CrRef (Figure 6). The c
2 test of this compari-
son yielded a significance probability of 0.25, sug-
gesting no significant difference between the 2 ROC
areas, and therefore no difference in performance for
predicting AKI.
Clinical Characteristics of Patients With Misclassified
AKI Status
We compared relevant clinical characteristics of the
patients who were incorrectly classified as either hav-
ing, or not having, AKI according to the eCr100M,
eCrAdmit, eCradjusted, and eCrCohort methods
(Supplementary Table 1). The age of patients with a
misclassified AKI status was significantly lower than
those correctly classified when assessed using the
eCrAdmit, eCradjusted, and eCrCohort methods (P ¼ 0.015,
P < 0.001, and P ¼ 0.049, respectively). There was no
difference in sex or weight between the groups thatKidney International Reports (2021) 6, 645–656were classified correctly or incorrectly for any of the
methods assessed.DISCUSSION
In this assessment of defining surrogate baseline creati-
nine values in community-acquired AKI during acute
infection, we have demonstrated that existing conven-
tional research methods may result in a large source of
potential error. Our results have significant implications
for epidemiological studies and clinical trials conducted
in these settings. AKI can result from a wide range of
pathological processes, with varying clinical courses and
outcomes. This analysis illustrates an additional pitfall
when conducting studies requiring the evaluation and
classification of AKI during a systemic infection.
The widely accepted practice of assuming a GFR of
75 ml/min and back-calculating an estimated baseline
creatinine15,33–37 using the methods described is inac-
curate in this setting and population, leading to653
CLINICAL RESEARCH DJ Cooper et al.: Classifying AKI in Acute Infectionunderestimation of AKI incidence by greater than 50%.
This underestimation is not surprising given that 75
ml/min is lower than both the mean (103  20 ml/min)
and median (104 [IQR 90–115] ml/min) follow-up GFR.
Despite being slightly lower than the median and mean
GFR, an assumed GFR of 100 ml/min overestimates AKI
incidence by 16% using the MDRD equation and
misclassifies AKI at all stages using the CKD-EPI
equation, despite having only a 3% total percentage
error.
In an intensive care unit population in New Zealand,
back-calculation using the MDRD equation and an
assumed GFR of either 75 or 100 ml/min performed no
better at estimating baseline creatinine than a random
number generator over a lognormal curve, and led to
an overestimation of AKI.38 We found a similar effect in
our dataset, with a randomly assigned creatinine over a
lognormal curve performing no better than back-
calculation methods. Most studies to date assessing
back-calculation of baseline creatinine have been in the
context of hospital-acquired AKI,14 leaving the classi-
fication of a baseline creatinine in community-acquired
AKI (as will be the case with most presentations of
infection associated AKI) even less certain.
The MDRD and the more recently derived CKD-EPI
equations were generated and validated in older North
American populations with high body mass indexes
and CKD.18,39 This analysis shows they are not appro-
priate or accurate measures in younger and/or lower
body mass index populations, or in those without CKD.
The MDRD equation is known to have limitations for
the estimation of GFR in healthy populations, with GFR
on average 26% higher in healthy persons than those
with CKD at the same serum creatinine concentration,
age, and sex.30 This limitation is evident from our
analysis of clinical characteristics, whereby we
demonstrate that participants with an incorrectly
identified AKI status have a significantly younger age
than those correctly identified.
The CKD-EPI equation is known to perform better at
estimating GFR19; however, in this study we found that
it is less accurate at back-calculating an estimated
baseline creatinine and at classifying AKI than the
MDRD equation. Further, this method involves more
complicated calculations, including the derivation of
individual age-specific reference points for each
assumed GFR. This study found that assigning a GFR
using age- and gender-specific values and correcting
for a non-CKD population has the greatest sensitivity
(94%), although at the expense of specificity (79%) and
overestimates total AKI incidence by nearly 50%.
The lowest measured creatinine during the first 72
hours of admission appears to be an acceptable surro-
gate for recovery creatinine, especially at classifying654stage 2 and 3 AKI, with similar sensitivity and speci-
ficity to back-calculation with the MDRD equation and
an assumed GFR of 100 ml/min, as well as similar
interrater agreement (kappa statistic) and AUC ROC. It
is not certain from these data, however, whether this
surrogate measure would perform as well for shorter
admissions, or less frequent creatinine measurements.
The lowest measured creatinine during admission ap-
pears to be the preferable surrogate for higher admis-
sion creatinine values, as it showed the smallest
proportional bias (which did not differ significantly
from zero), indicating the distribution does not differ
significantly from the measured distribution at higher
creatinine values.
This study has several limitations. There is no ac-
curate classification of the population distribution of
baseline creatinine values in any Southeast Asian
population in good health or during illness. This pre-
sents difficulties for accurate comparison of surrogate
creatinine values. Given these limitations, the recovery
creatinine at 28 days is likely the best estimate of
premorbid baseline creatinine in most patients
analyzed here. In a retrospective cohort study of crit-
ically ill North American adults in an intensive care
unit, 88% of patients experienced renal recovery 3
months after discharge.40 The patients in that study
were older, with significant comorbidities and a lower
median GFR at enrollment, and the degree of AKI was
more severe and associated with a high mortality rate
(25.6%). In contrast, most patients in this study had
AKI stage 1 or 2, those requiring RRT were omitted,
and there were no fatalities; thus, a higher proportion
of patients would be expected to have recovered to a
premorbid baseline in a shorter timeframe. The 5 pa-
tients requiring RRT acutely were excluded from
comparison of back-calculation methods; however,
interpretation of the creatinine kinetics, and therefore
defining an expected absolute creatinine value, in the
context of acute RRT of varying durations and mo-
dalities was not feasible for inclusion in this analysis.
This study included patients from a very specific
population and clinical context; however, acute in-
fections frequently occur in younger populations and
in low- and middle-income countries. These pop-
ulations are unlikely to have a well-defined distribu-
tion of GFR in good health or disease, and therefore the
need to carefully consider and report surrogate creati-
nine estimates in acute infection is a generalizable
conclusion. Finally, there were relatively few women
included; however, this is unlikely to have affected the
inference due to sex coefficients included within the
formulae assessed.
Epidemiological studies or clinical trials in acute
infection are prone to errors in classification of AKI byKidney International Reports (2021) 6, 645–656
DJ Cooper et al.: Classifying AKI in Acute Infection CLINICAL RESEARCHback-calculating using standard methods, and in
particular may miss small, short-term changes in
creatinine or small treatment effects. If back-calculation
is necessary, assuming a GFR of 100 ml/min in a
younger population with community-acquired acute
infection without multiple comorbidities is likely to be
more accurate than assuming a GFR of 75 ml/min, with
the MDRD method preferable to CKD-EPI. This may
reflect the fact that the mean population eGFR was 103
ml/min, also suggesting that using a mean population
(or cohort) GFR for back-calculating creatinine is likely
to be more accurate than assuming an arbitrary GFR
value. Obtaining a population distribution of baseline
GFR values or an estimate of a distribution using re-
covery values in a specific cohort would likely improve
back-calculations of estimated baseline creatinine, and
provide more accurate classifications of AKI.
Whichever method is chosen to define surrogate
baseline creatinine values for classification of AKI in
clinical trials or epidemiological studies, it is essential
that investigators clearly define the chosen method, the
definition of AKI, justify any assumptions made, and
that methods used are consistent across and within
studies where possible. These methodological issues
will persist until improved baseline creatinine distri-
butions exist for different populations, or until a su-
perior biomarker for AKI becomes available.
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